Abstract
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available to the medical oncologist for care of patients with metastatic breast cancer. We will briefly review the new advances in the treatment of metastatic breast cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | S132-S137 |
| Journal | Clinical orthopaedics and related research |
| Volume | 415 |
| Issue number | SUPPL. |
| DOIs | |
| State | Published - Oct 2003 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Surgery
- Orthopedics and Sports Medicine
Fingerprint
Dive into the research topics of 'Metastatic Breast Cancer: Overview of Treatment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver